Business Wire8h
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Ever-Growing USA on MSN15h
Cell Line Development Process – Challenges and Best Practices
Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.
precisionmedicineonline21h
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...
Maze Therapeutics doses first patient in Phase 2 HORIZON trial
Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...
Jane's Information Group2d
Iran claims to have integrated S-300 components with indigenous Bavar-373
The Islamic Republic of Iran Air Defence Force (IRIADF) has successfully integrated its Bavar-373 indigenous long-range ...
Trump won't rule out deploying US troops to support rebuilding Gaza, sees 'long-term' US ownership
President Donald Trump has suggested that displaced Palestinians in Gaza be permanently resettled outside the war-torn territory and proposed the U.S. take “ownership” in redeveloping the area.